NCT04355143View on ClinicalTrials.gov

Colchicine to Reduce Cardiac Injury in COVID-19 (COLHEART-19)

PHASE2CompletedINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

May 1, 2020

Primary Completion Date

July 21, 2021

Study Completion Date

July 21, 2021

Conditions
COVID-19
Interventions
DRUG

Colchicine Tablets

COLCRYS (colchicine, USP) tablets for oral administration, containing 0.6 mg of the active ingredient colchicine USP, administered po every 12 hours x 30 days.

OTHER

Current care per UCLA treating physicians

Current care

Trial Locations (3)

33176

Miami Cardiac and Vascular Institutde, Baptist Health South Florida, Miami

90095

UCLA Ronald Reagan Medical Center, Los Angeles

90404

UCLA Santa Monica Hospital, Santa Monica

All Listed Sponsors
lead

University of California, Los Angeles

OTHER

NCT04355143 - Colchicine to Reduce Cardiac Injury in COVID-19 (COLHEART-19) | Biotech Hunter | Biotech Hunter